Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT04702360
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ELX/TEZ/IVADrug: IVA
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 69
- Registration Number
- NCT04599465
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Montpellier Cedex 5, France
🇧🇪Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ELX/TEZ/IVADrug: IVA
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 120
- Registration Number
- NCT04545515
- Locations
- 🇦🇺
Telethon Kids Institute, Nedlands, Australia
🇦🇺Queensland Children's Hospital, South Brisbane, Australia
🇦🇺The Children's Hospital at Westmead, Westmead, Australia
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ELX/TEZ/IVADrug: IVA
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 83
- Registration Number
- NCT04537793
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Drug: VX-864Drug: Placebo
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 44
- Registration Number
- NCT04474197
- Locations
- 🇺🇸
Blessing Corporate Services, Inc., dba Blessing Health System, Hannibal, Missouri, United States
🇺🇸Cardinal Glennon Children's Hospital - St. Louis University, Saint Louis, Missouri, United States
🇩🇪Universitätsklinikum Essen, Essen, Germany
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ELX/TEZ/IVADrug: IVA
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 172
- Registration Number
- NCT04362761
- Locations
- 🇦🇺
Telethon Kids Institute, Perth Children's Hospital, Nedlands, Australia
🇦🇺The Royal Children's Hospital, Parkville, VIC, Australia
🇦🇺Queensland Children's Hospital, South Brisbane, Australia
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ELX/TEZ/IVAOther: Placebo (matched to ELX/TEZ/IVA)Other: Placebo (matched to IVA)Drug: IVA
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 121
- Registration Number
- NCT04353817
- Locations
- 🇦🇺
Queensland Children's Hospital, South Brisbane, Australia
🇦🇺The Children's Hospital at Westmead, Westmead, Australia
🇦🇺Telethon Kids Institute, Nedlands, Australia
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
- Conditions
- Glomerulosclerosis, Focal Segmental
- Interventions
- Drug: VX-147
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT04340362
- Locations
- 🇺🇸
Florida Premier Research Institute, Winter Park, Florida, United States
🇺🇸Central Georgia Kidney Specialists PC, Macon, Georgia, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: LUM/IVA
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 52
- Registration Number
- NCT04235140
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Long-term Follow-up Study in Participants Who Received CTX001
- Conditions
- Beta-ThalassemiaSickle Cell AnemiaGenetic Diseases, InbornHemoglobinopathiesHematologic DiseasesThalassemiaSickle Cell Disease
- Interventions
- Biological: CTX001
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 160
- Registration Number
- NCT04208529
- Locations
- 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States